Fundraising Fox
NervGen Pharma
NASDAQ: NGENFounded 2017 · British Columbia, Canada corporation · 2 known investors
Find your way into NervGen Pharma
Sign up to see every warm intro you have to NervGen Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NervGen Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Founders & leadership
NervGen Pharma was founded in 2017 by Harold Punnett and Jerry Silver.
JS
Jerry SilverCo-founder
WA
William AdamsExecutive
DM
Daniel MikolChief Medical Officer2021–2025Daniel Mikol is an executive at NervGen Pharma, a clinical-stage biotech company developing therapies for neurological conditions including spinal cord injury. He has experience in clinical drug development across all phases with a focus on neuroscience.
RK
Randall KayeNamed on SEC filing
BB
Brian BayleyNamed on SEC filing
MA
Michael AbramsNamed on SEC filing
BR
Bill RadvakNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 7 rounds · 2018–2021
▶$651.8KraisedDec 2021 · 17 investors · OtherRule 506(b)
▶$651.8KraisedDec 2021 · 17 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Harold PunnettDirector
- Michael AbramsDirector
- Brian BayleyDirector
- Bill RadvakDirector
- Paul BrennanDirector, Executive Officer
- Randall KayeDirector
- Daniel MikolExecutive Officer
- Glenn IvesDirector
- Krista McKerracherDirector
- William AdamsExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $651.8K
- First sale
- Nov 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$2.2MraisedAug 2021 · 23 investors · OtherRule 506(b)
▶$2.2MraisedAug 2021 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Randall KayeDirector
- Brian BayleyDirector
- Daniel MikolExecutive Officer
- Bill RadvakDirector
- Michael AbramsDirector
- Paul BrennanDirector, Executive Officer
- William AdamsExecutive Officer
- Harold PunnettDirector
- Offering amount
- $5.4M
- Amount sold
- $2.2M
- Sales commissions
- $153.6K
- Placement agents
- Arcadia Securities, LLC, Haywood Securities (USA) Inc.
- First sale
- Aug 2020
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$263.7KraisedAug 2021 · 3 investors · OtherRule 506(b)
▶$263.7KraisedAug 2021 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian BayleyDirector
- William AdamsExecutive Officer
- Michael AbramsDirector
- Randall KayeDirector
- Bill RadvakDirector
- Daniel MikolExecutive Officer
- Paul BrennanDirector, Executive Officer
- Harold PunnettDirector
- Offering amount
- $442.3K
- Amount sold
- $263.7K
- First sale
- Aug 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$285.1KraisedJun 2021 · 13 investors · OtherRule 506(b)
▶$285.1KraisedJun 2021 · 13 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Randall KayeDirector
- William AdamsExecutive Officer
- Brian BayleyDirector
- Harold PunnettDirector
- Michael AbramsDirector
- Paul BrennanDirector, Executive Officer
- Bill RadvakDirector
- Daniel MikolExecutive Officer
- Offering amount
- $650.1K
- Amount sold
- $285.1K
- First sale
- May 2020
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$1.5MraisedNov 2019 · 1 investors · OtherRule 506(b)
▶$1.5MraisedNov 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Ernest WongExecutive Officer, Director
- Robert PilzExecutive Officer
- Amy FrankeExecutive Officer
- Harold PunnettDirector
- Bill RadvakExecutive Officer, Director
- Michael AbramsDirector
- Brian BayleyDirector
- Denis BoscExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Nov 2019
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$1.2MraisedMar 2019 · 28 investors · OtherRule 506(b)
▶$1.2MraisedMar 2019 · 28 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Harold PunnettDirector
- William Joseph RadvakExecutive Officer, Director
- Brian BayleyDirector
- Robert PilzExecutive Officer
- Ernest WongExecutive Officer, Director
- Michael Jeffrey AbramsDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- Sales commissions
- $83.8K
- Placement agents
- Haywood Securities (USA) Inc.
- First sale
- Mar 2019
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$111.4KraisedSep 2018 · 5 investors · OtherRule 506(b)
▶$111.4KraisedSep 2018 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- HAROLD MARTIN PUNNETTDirector
- WILLIAM JOSEPH RADVAKExecutive Officer, Director, Promoter
- ROBERT GERHARD PILZExecutive Officer
- ERNEST SHINGYAN WONGExecutive Officer, Director
- MICHAEL JEFFREY ABRAMSDirector
- BRIAN ERIC BAYLEYDirector
- Offering amount
- $111.4K
- Amount sold
- $111.4K
- First sale
- Sep 2018
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through NervGen Pharma went on to found or lead other companies.
Related companies · 6
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Companies working in the same space as NervGen Pharma.
Frequently asked questions
- What does NervGen Pharma do?
- NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
- Who founded NervGen Pharma?
- NervGen Pharma was founded by Harold Punnett, Jerry Silver in 2017.
- Who are NervGen Pharma's investors?
- NervGen Pharma's investors include CWRU Technology Ventures, SCI Ventures.
- How much funding has NervGen Pharma raised?
- NervGen Pharma has disclosed $6.2M raised across 7 rounds.